Tests PBGENE-HBV in adults with chronic hepatitis B
Tests PBGENE-HBV for safety and antiviral effect in adults with chronic hepatitis B.
Plain-language title generated from the registry record
Registry title: Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
Key facts
- Where
- Auckland, New ZealandSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06680232, who can take part
Where in New Zealand
- New Zealand Clinical ResearchAuckland, New ZealandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Precision BioSciences, Inc.
- Trial code
- NCT06680232EU 2025-524157-13-00
- Record updated
- 24 August 2026
- Original description
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.Read full original descriptionShow less
A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B)
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
Inclusion: Male or women of non-child bearing potential; BMI 18.0 to 35.0; Good overall health deemed by the study Investigator; CHB infection documented at least 12 months prior to screening; HBeAg-negative CHB; Must be virologically suppressed on current NA treatment.
Exclusion: Not received an organ transplant; No investigational agent received within 6 months of screening; No history of cirrhosis of the liver; No current infections of Hepatitis A, D, and E, human immunodeficiency virus (type 1 and 2), and no history of or current hepatitis C. In addition, no other active infections deemed clinically relevant; No malignancy within 5 years of screening, except for specific cancers that are cured by surgical resection (e.g., basal cell skin cancer); No signs of hepatocellular carcinoma.